GlassScriptPhysician profile
Charles H Redfern
NPI 1225007396
$588.58
in general payments reported to CMS, 2019-2025
24 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.17 · 2020: $36.30 · 2023: $108 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monteris Medical Corporation | $231.40 | 2025 | Neuroblate |
| Genzyme Corporation | $204.48 | 2019-2025 | |
| Tempus Ai, INC | $55.63 | 2025 | Xt Cdx |
| Daiichi Sankyo INC. | $36.30 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.32 | 2019 | |
| Siemens Medical Solutions USA, INC. | $15.36 | 2023 | Varian Ethos Treatment Planning |
| Merck Sharp & Dohme LLC | $14.31 | 2019 | |
| Genentech USA, INC. | $11.78 | 2019 |
16 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Redfern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.